(MedPage Today) — The FDA granted accelerated approval to sibeprenlimab injection (Voyxact) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy at risk for disease progression, the agency announced on Tuesday…
Source link : https://www.medpagetoday.com/nephrology/generalnephrology/118740
Author :
Publish date : 2025-11-26 16:44:00
Copyright for syndicated content belongs to the linked Source.
